Abstract:e14006 Background: Radiation necrosis (RN) is post-radiation complication that leads to increased permeability and disruption of the blood brain barrier (BBB). This in turn leads to a pro-inflammatory state and an increased production of vascular-endothelial growth factor (VEGF). Bevacizumab is a monoclonal antibody against VEGF and is a potential treatment for RN. The objective of the study is to assess effectiveness of bevacizumab (BEV) for the treatment of brain RN in adults. Methods: Retrospective chart review of 22 patients with various solid malignancies including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), metastatic melanoma and breast cancer with clinical or radiographic diagnosis of RN seen at Memorial Cancer Institute (MCI) in a 3-year period, from January 1 st , 2019 to January 1 st , 2023. Radiation doses ranged from 18-24 Gy (single fraction) or 24-27 Gy (3-fraction) for radiosurgery and 30-37.5 Gy for whole brain radiotherapy. Patients were identified that developed RN and VEGF inhibitors were subsequently given to assess effectiveness in the treatment of the condition. We evaluated the dose, frequency, number of treatments received, adverse effects and therapeutic benefits of BEV. Therapeutic benefit was defined as patients that received bevacizumab had a radiological and clinical improvement of the RN (clinical benefit). Brain imaging with MRI or PET/CT scan was completed both pre and post treatment to evaluate efficacy of treatment. Patients were initially given 4 cycles with a subsequent 4 more cycles if it was beneficial and tolerated treatment. Results: 22 patients were included in the study, 9 were males (41%) and median age 66 (range 31-81). 91% (20/22) had a diagnosis of lung cancer. 1 patient had a diagnosis of SCLC, while 19 were diagnosed with NSCLC. The study had a good representation of different races including Non-Hispanic Whites 7 (32%), Hispanics 10 (45%), Blacks 13% (3) and Asians 10% (2). Over 95% (21/22) of patients achieved a clinical benefit, while one patient did not (5%). Patients experienced improvement in cognitive function, headaches, dizziness, weakness, and other symptoms with BEV. MRIs showed improvement in edema and a reduction/stabilization of brain lesions. The most frequent dosing regimen used was BEV 10 mg/kg every two weeks. The median number of cycles given was 4 cycles (1-12). The most common adverse events were hypertension, minor nose bleeding, an occasional protein found in urine. There were no severe AEs or discontinuation of therapy with bevacizumab. Conclusions: This study demonstrated treatment with BEV 10 mg/kg every two weeks for a total of 12 cycles is well tolerated and has potential clinical benefit in RN in lung cancer patients with CNS metastasis. The therapeutic effects of VEGF inhibitors were seen in our small population study but warrants further investigation in a larger population study.

Severe thrombocytopenia associated to bevacizumab in a patient with scleroderma, gastrointestinal angiodysplasias and refractory gastrointestinal bleeding

Glanzmann's thrombasthenia associated with gastrointestinal angiodysplasias successfully treated with bevacizumab

Severe Esophageal Bleeding in Colorectal Cancer Due to Antitumor Therapy: A Case Report

Bevacizumab-induced immune thrombocytopenia in an ovarian cancer patient with mixed connective tissue disease: case report and literature review

Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database

S3648 Role of Bevacizumab in Hereditary Hemorrhagic Telangiectasia Associated Recurrent Gastrointestinal Bleeding: A Case Report

Bevacizumab for the treatment of metastatic colorectal cancer complicated by abdominal aortic aneurysm and mural thrombus: a case report

Total and Not Bevacizumab-Bound Vascular Endothelial Growth Factor As Potential Predictive Factors to Bevacizumab-Based Chemotherapy in Colorectal Cancer.

Outcomes with bevacizumab for radiation induced-brain necrosis.

Haemorrhagic shock secondary to aorto-enteric fistula after treatment with bevacizumab for metastatic colorectal cancer: review of the literature

[Portal vein thrombosis and nodular regenerative hyperplasia associated with the use of bevacizumab and oxaliplatin. Report of one case]

Celiac trunk aortic dissection induced by bevacizumab therapy for rectal cancer: A case report

Long-Term Relief of Cerebral Radiation Necrosis Treated with Low-Dose Bevacizumab - a Report of 2 Cases

Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis

Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia

Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta‐analysis

[A case of severe bevacizumab-induced ischemic pancolitis, treated with conservative management]

Adverse reactions of bevacizumab in the treatment of malignant tumor

Rare Case of Endoscopic Treatment for Bevacizumab-Related Gastric Perforation in a Patient with Ovarian Cancer

Secondary spontaneous pneumothorax during chemotherapy with bevacizumab for cervical cancer: a case report and literature review

Bevacizumab-Related Surgical Site Complication Despite Primary Tumor Resection in Colorectal Cancer Patients